Capvizr
THE DEAL, AT A GLANCE

Cloverleaf Bio

2/4 explanations supported
01
MoleculesDrug research
Medicine development
What it doesCloverleaf Bio develops RNA-based medicines intended to treat cancer.Source-grounded · automated review · Explore ↗

Checked 2026-09-09 · Review due 2026-09-16

Read supporting source ↗
Developing a new class of…
02Who is involvedEvidence still neededOpen review status ↗

The draft does not name investors and states that no source document names investors or distinguishes roles. That is accurate for the provided document.

03What happenedEvidence still neededOpen review status ↗

The $33M Seed round is supported by “Cloverleaf Raises $33M Seed Round.” However, the target date 2026-09-08 is not supported by the provided document, and the draft’s eventMatch=true is therefore not fully justified. The document also does not distinguish announcement date from page/copyright date.

04Why it mattersThe seed funding supports a cancer-medicine company that says it is hiring.Interpretation · Explore ↗

Checked 2026-09-09 · Review due 2026-09-16

Read supporting source ↗
Developing a new class of…
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Cloverleaf Bio · Financing Record

Explore source-linked visual explanations for Cloverleaf Bio. Unsupported claims are withheld while source review continues.

Record 11874 · Recorded date: 2026-09-08

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime